Literature DB >> 9691705

Potential drug-drug interactions on a tertiary-care hospital consultation-liaison psychiatry service.

D E Adson1, S J Crow, W H Meller, R M Magraw.   

Abstract

Pharmacokinetic interactions involving the cytochrome P450 system have been a recent focus of clinical and research interest in psychopharmacology. The authors reviewed 100 consecutive patients seen on a consultation-liaison (C-L) psychiatry service for potential drug-drug interactions. The patients were taking a mean of 8.8 medications; for those undergoing organ transplantation the mean was 12.9. While both enzyme inhibitors (n = 87) and substrates (n = 89) were commonly used, only rarely were they used in the same patient (n = 14). The authors conclude that the potential for drug interactions on a C-L psychiatry service is significant, necessitating awareness of this potential complication.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9691705     DOI: 10.1016/S0033-3182(98)71324-6

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  3 in total

Review 1.  Patient-oriented strategies for the prevention of drug interactions.

Authors:  C P Alderman
Journal:  Drug Saf       Date:  2000-02       Impact factor: 5.606

2.  Absolute contraindications in relation to potential drug interactions in outpatient prescriptions: analysis of the first five million prescriptions in 1999.

Authors:  Laurence Guédon-Moreau; Dominique Ducrocq; Marie-Francoise Duc; Yves Quieureux; Catherine L'Hôte; Jean Deligne; Jacques Caron
Journal:  Eur J Clin Pharmacol       Date:  2003-12-19       Impact factor: 2.953

3.  Absolute contraindications in relation to potential drug interactions in outpatient prescriptions: analysis of the first five million prescriptions in 1999.

Authors:  Laurence Guédon-Moreau; Dominique Ducrocq; Marie-Francoise Duc; Yves Quieureux; Catherine L'Hôte; Jean Deligne; Jacques Caron
Journal:  Eur J Clin Pharmacol       Date:  2003-10-14       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.